TY - JOUR
T1 - Intravenous vitamin C for vasoplegia
T2 - A double-blinded randomised clinical trial (VALENCIA trial)
AU - Anstey, Matthew H.
AU - Aljeaidi, Muhamad S.
AU - Palmer, Robert
AU - Jacques, Angela
AU - Mevavala, Bhaumik
AU - Litton, Edward
AU - Wibrow, Bradley
N1 - Funding Information:
This trial was supported by a grant from the Sir Charles Gairdner Hospital Research Foundation . The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data.
Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/12
Y1 - 2023/12
N2 - Purpose: To determine whether intravenous vitamin C compared with placebo, reduces vasopressor requirements in patients with vasoplegic shock. Methods: Double-blinded, randomised clinical trial (RCT) conducted in two intensive care units in Perth, Australia. Vasopressor requirements at enrolment needed to be >10 μg/min noradrenaline after hypovolaemia was clinically excluded. Patients received either intravenous 1.5 g sodium ascorbate in 100 ml normal saline every 6 h for 5 days, or placebo (100 ml normal saline). The primary outcome was duration of vasopressor usage in hours. Secondary outcomes were ICU and hospital length of stay, and 28-day, ICU and hospital mortality. Results: Of the 71 patients randomised (35 vitamin C, 36 placebo group), the median vasopressor duration was 44 h [95% CI, 37–54 h] and 55 h [95% CI, 33–66 h]) in the vitamin C and placebo groups (p = 0.057). ICU and hospital length of stay, mortality outcomes were similar between groups. Conclusions: In this RCT of patients with vasoplegic shock of at least moderate severity, the use of IV vitamin C compared with placebo did not significantly reduce the duration of vasopressors. Trial registration: Prospective registration – trial number ACTRN12617001392358.
AB - Purpose: To determine whether intravenous vitamin C compared with placebo, reduces vasopressor requirements in patients with vasoplegic shock. Methods: Double-blinded, randomised clinical trial (RCT) conducted in two intensive care units in Perth, Australia. Vasopressor requirements at enrolment needed to be >10 μg/min noradrenaline after hypovolaemia was clinically excluded. Patients received either intravenous 1.5 g sodium ascorbate in 100 ml normal saline every 6 h for 5 days, or placebo (100 ml normal saline). The primary outcome was duration of vasopressor usage in hours. Secondary outcomes were ICU and hospital length of stay, and 28-day, ICU and hospital mortality. Results: Of the 71 patients randomised (35 vitamin C, 36 placebo group), the median vasopressor duration was 44 h [95% CI, 37–54 h] and 55 h [95% CI, 33–66 h]) in the vitamin C and placebo groups (p = 0.057). ICU and hospital length of stay, mortality outcomes were similar between groups. Conclusions: In this RCT of patients with vasoplegic shock of at least moderate severity, the use of IV vitamin C compared with placebo did not significantly reduce the duration of vasopressors. Trial registration: Prospective registration – trial number ACTRN12617001392358.
KW - Intensive care
KW - Randomised controlled trial
KW - Vasoplegic shock
KW - Vitamin C
UR - http://www.scopus.com/inward/record.url?scp=85165289474&partnerID=8YFLogxK
U2 - 10.1016/j.jcrc.2023.154369
DO - 10.1016/j.jcrc.2023.154369
M3 - Article
C2 - 37478532
AN - SCOPUS:85165289474
SN - 0883-9441
VL - 78
JO - Journal of Critical Care
JF - Journal of Critical Care
M1 - 154369
ER -